Imagion Biosystems Ltd. has released a press release.
MagSense Nanoparticle Manufacturing Update
Earlier from Imagion Biosystems
- IBX Phase 2 Clinical Trial Update
- Appendix 4C and Quarterly Activities Report - June 2026
- Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
- IBX Secures Firm Commitments for $3.75m for Clinical Trial